Med BioGene Inc. (MBI.V) Wednesday reported a first quarter loss of $121 thousand, narrower than $197 thousand in the same quarter last year. On a per share basis, earnings were breakeven, flat with last year.
MBI did not incur any research and development expenses throughout the quarter, as its partner Precision Therapeutics, Inc., was responsible for all future costs associated with the development and commercialization of MBI's flagship test, LungExpress Dx, as announced in an agreement. In the prior year, Med BioGene has recorded R&D expenses of $42 thousand.
General and administrative expenses for the quarter increased 13 percent to $121 thousand from $107 thousand last year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.